Soligenix, Inc. - Common Stock (SNGX)

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

Discover the most active stocks in Monday's session. Stay informed about the stocks that are generating the most trading volume!

Soligenix shares surge after FDA granted orphan drug designation to dusquetide for Behçet's Disease, boosting prospects for rare disease treatment.

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Let's have a look at the gap up and gap down stocks in today's session.

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Unusual volume stocks are being observed in Monday's session.

Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.

Get a pulse on the US markets on Thursday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

Soligenix reports positive Phase 2a trial results for SGX945 in Behçet's disease, showing strong efficacy and no adverse events compared to apremilast.